CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today the appointment of Mitchell Finer, Ph.D. as Chief Scientific Officer. Dr. Finer brings over 20 years of biotech experience and is a pioneer in the field of gene therapy and regenerative medicine. At Genetix Pharmaceuticals, Dr. Finer will provide scientific leadership for the development platform capabilities and therapeutic approaches with the company’s current technology platform, as well as focus on the long-term strategic scientific and clinical direction of the company.
